Phase 1 Study to Assess Safety and Efficacy of ANG003

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency. The study\'s overall objectives are to evaluate the safety, tolerability and effect of four dose levels of ANG003.
Epistemonikos ID: b50e69faed6129f3c10481c378ea2dd39eccc7d0
First added on: May 15, 2024